Rare Diseases: Drug Discovery and Informatics Resource

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Interdisciplinary Sciences Computational Life Sciences

• Publication date

  2017-11-01

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1007/s12539-017-0270-3PMID 29094320
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Challenges in orphan drug development and regulatory policy in China

  2017cited by this paper
• Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges

  2017cited by this paper
• Drug discovery and development for rare genetic disorders

  2017cited by this paper
• Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry

  2017cited by this paper
• Innovative measures to combat rare diseases in China: The national rare diseases registry system, larger-scale clinical cohort studies, and studies in combination with precision medicine research.

  2017cited by this paper
• Rare advances for rare diseases.

  2017cited by this paper
• Rare Diseases: A Current View

  2017cited by this paper
• Defining rare diseases in China.

  2017cited by this paper
• The management and treatment of children with Fabry disease: A United States-based perspective.

  2016cited by this paper
• Migalastat: First Global Approval

  2016cited by this paper
• Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.

  2016cited by this paper
• Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease

  2016cited by this paper
• Gene therapy for sickle cell disease.

  2016cited by this paper
• Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors.

  2016influential reference
• Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm

  2016cited by this paper
• Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients

  2016cited by this paper
• Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65

  2016cited by this paper
• Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.

  2016cited by this paper
• Gene therapy: Industrial strength

  2016cited by this paper
• Scoring multiple features to predict drug disease associations using information fusion and aggregation

  2016cited by this paper
• Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.

  2016cited by this paper
• Enzyme replacement therapy for Anderson-Fabry disease.

  2016cited by this paper
• Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy.

  2015cited by this paper
• NIH/NCATS/GRDR® Common Data Elements: A leading force for standardized data collection.

  2015cited by this paper
• Improvement and decline in vision with gene therapy in childhood blindness.

  2015cited by this paper
• DrugNet: Network-based drug-disease prioritization by integrating heterogeneous data

  2015cited by this paper
• The human Drug-Disease-Gene Network

  2015cited by this paper
• Gene therapy returns to centre stage

  2015cited by this paper
• The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease.

  2015cited by this paper
• Drug repositioning can accelerate discovery of pharmacological chaperones

  2015cited by this paper
• The α7 nAChR selective agonists as drug candidates for Alzheimer's disease.

  2015cited by this paper
• PhenomeCentral: A Portal for Phenotypic and Genotypic Matchmaking of Patients with Rare Genetic Diseases

  2015cited by this paper
• Computational and experimental advances in drug repositioning for accelerated therapeutic stratification.

  2015cited by this paper
• FORGE Canada Consortium: outcomes of a 2-year national rare-disease gene-discovery project.

  2014cited by this paper
• Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR)

  2014cited by this paper
• A Network-Based Classification Model for Deriving Novel Drug-Disease Associations and Assessing Their Molecular Actions

  2014cited by this paper
• Systems biology brings new dimensions for structure-based drug design.

  2014cited by this paper
• Treatment of lysosomal storage diseases: recent patents and future strategies.

  2014cited by this paper
• OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders

  2014cited by this paper
• Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines.

  2014cited by this paper
• Drug-Disease Association and Drug-Repositioning Predictions in Complex Diseases Using Causal Inference-Probabilistic Matrix Factorization

  2014cited by this paper
• Multi-algorithm and multi-model based drug target prediction and web server

  2014cited by this paper
• Anderson-Fabry Disease and Other Lysosomal Storage Disorders

  2014cited by this paper
• The incorporation of protein flexibility and conformational energy penalties in docking screens to improve ligand discovery

  2014cited by this paper
• Elosulfase alfa: First Global Approval

  2014cited by this paper
• Pathway-based Bayesian inference of drug-disease interactions.

  2014cited by this paper
• Orphan Drugs and Rare Diseases

  2014cited by this paper
• Exploring the Ligand-Protein Networks in Traditional Chinese Medicine: Current Databases, Methods, and Applications

  2013cited by this paper
• ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method

  2013cited by this paper
• Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters (CAGCs)

  2013influential reference
• The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases

  2013cited by this paper
• Orphanet et son réseau : où trouver une information validée sur les maladies rares

  2013cited by this paper
• Enzyme replacement therapy for Anderson-Fabry disease.

  2013cited by this paper
• Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones

  2013cited by this paper
• [Orphanet and its consortium: where to find expert-validated information on rare diseases].

  2013cited by this paper
• Drug-Domain Interaction Networks in Myocardial Infarction

  2013cited by this paper
• Network-based drug repositioning.

  2013cited by this paper
• Drug repositioning framework by incorporating functional information.

  2013cited by this paper
• Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS) - registry Swabia

  2013cited by this paper
• A CTD–Pfizer collaboration: manual curation of 88 000 scientific articles text mined for drug–disease and drug–phenotype interactions

  2013cited by this paper
• Allogeneic cellular gene therapy in hemoglobinopathies—evaluation of hematopoietic SCT in sickle cell anemia

  2012cited by this paper
• Representation of rare diseases in health information systems: The orphanet approach to serve a wide range of end users

  2012cited by this paper
• DECIPHER: web-based, community resource for clinical interpretation of rare variants in developmental disorders.

  2012cited by this paper
• Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference

  2012cited by this paper
• A Pharmacological Organization of G Protein-coupled Receptors

  2012cited by this paper
• Gene therapy for sickle cell disease.

  2012cited by this paper
• Use of genome-wide association studies for drug repositioning

  2012cited by this paper
• Rare diseases and orphan drugs

  2012cited by this paper
• Predicting drug targets based on protein domains.

  2012cited by this paper
• Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets

  2012cited by this paper
• If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD).

  2012cited by this paper
• Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases

  2011cited by this paper
• Exploring Off-Targets and Off-Systems for Adverse Drug Reactions via Chemical-Protein Interactome — Clozapine-Induced Agranulocytosis as a Case Study

  2011cited by this paper
• Mining Significant Substructure Pairs for Interpreting Polypharmacology in Drug-Target Network

  2011cited by this paper
• Disease Ontology: a backbone for disease semantic integration

  2011cited by this paper
• Modularity-based credible prediction of disease genes and detection of disease subtypes on the phenotype-gene heterogeneous network

  2011cited by this paper
• Drug repositioning for orphan diseases

  2011cited by this paper
• Gene therapies advance towards finish line

  2011cited by this paper
• RAMEDIS: a comprehensive information system for variations and corresponding phenotypes of rare metabolic diseases

  2010cited by this paper
• Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks.

  2010cited by this paper
• Discovery of drug mode of action and drug repositioning from transcriptional responses

  2010cited by this paper
• Identification of small molecules enhancing autophagic function from drug network analysis

  2010cited by this paper
• Molecular networks for the study of TCM Pharmacology

  2010cited by this paper
• Systems approaches to polypharmacology and drug discovery.

  2010cited by this paper
• PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach

  2010cited by this paper
• Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency

  2010cited by this paper
• Unveiling the role of network and systems biology in drug discovery.

  2010cited by this paper
• Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.

  2010cited by this paper
• Kinetic modelling of NSAID action on COX-1: focus on in vitro/in vivo aspects and drug combinations.

  2009cited by this paper
• Comparative analysis of module-based versus direct methods for reverse-engineering transcriptional regulatory networks

  2009cited by this paper
• Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses

  2009cited by this paper
• Modeling of the Bacterial Mechanism of Methicillin-Resistance by a Systems Biology Approach

  2009cited by this paper
• Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

  2009cited by this paper
• The topology of drug-target interaction networks: implicit dependence on drug properties and target families.

  2009cited by this paper
• Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance

  2009cited by this paper
• Predicting new molecular targets for known drugs

  2009cited by this paper
• Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration

  2009cited by this paper
• Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib mice.

  2009cited by this paper
• Drug Target Identification Using Side-Effect Similarity

  2008cited by this paper
• Network-based global inference of human disease genes

  2008cited by this paper

• FCMSTrans: Accurate Prediction of Disease-Associated nsSNPs by Utilizing Multiscale Convolution and Deep Feature Combination within a Transformer Framework

  2024cites this paper
• Rare Disease Research Resources at the Rat Genome Database.

  2023cites this paper
• Emerging approaches to induce immune tolerance to therapeutic proteins.

  2023cites this paper
• Review of the Chinese Landscape in Phase 1 Clinical Trials for Noncancer Innovative Drugs Over 2015 to 2020

  2022cites this paper
• Studies on the Mechanism of Gegen Qinlian Decoction in Treating Diabetes Mellitus Based on Network Pharmacology

  2021cites this paper
• Drug Repurposing for Rare Diseases.

  2021cites this paper
• Knowledge-based approaches to drug discovery for rare diseases.

  2021cites this paper
• DeepnsSNPs: Accurate prediction of non-synonymous single-nucleotide polymorphisms by combining multi-scale convolutional neural network and residue environment information

  2021cites this paper
• Lessons learned from hemolytic uremic syndrome registries: recommendations for implementation

  2021cites this paper
• Clinical application of whole-exome sequencing: A retrospective, single-center study

  2021cites this paper
• Evolution of Biochip Technology: A Review from Lab-on-a-Chip to Organ-on-a-Chip

  2020cites this paper
• Ion channels as therapeutic targets for type 1 diabetes mellitus.

  2020cites this paper
• Approaching Complex Diseases: Network-Based Pharmacology and Systems Approach in Bio-Medicine

  2020cites this paper
• Mining Complex Biomedical Literature for Actionable Knowledge on Rare Diseases

  2020cites this paper
• The Biennial report: The collaboration between MAGI Research, Diagnosis and Treatment Center of Genetic and Rare Diseases and Near East University DESAM Institute

  2020cites this paper
• Exploring the Papillomaviral Proteome to Identify Potential Candidates for a Chimeric Vaccine against Cervix Papilloma Using Immunomics and Computational Structural Vaccinology

  2019cites this paper
• Computational Advances in the Label-free Quantification of Cancer Proteomics Data.

  2019cites this paper
• Biological Network Approaches and Applications in Rare Disease Studies

  2019cites this paper
• VCF‐Server: A web‐based visualization tool for high‐throughput variant data mining and management

  2019cites this paper
• Advances in Chitin/Chitosan Characterization and Applications

  2019cites this paper
• Identification of novel drug targets for diamond-blackfan anemia based on RPS19 gene mutation using protein-protein interaction network

  2018cites this paper
• CDG Therapies: From Bench to Bedside

  2018cites this paper
• Two-Dimensional Infrared Spectra of Cationic Dopamine under Different Electric Fields: Theoretical Studies from the Density Function Theory Anharmonic Potential

  2018cites this paper
• Development of a modular in vivo reporter system for CRISPR-mediated genome editing and its therapeutic applications for rare genetic respiratory diseases

  2018cites this paper
• Designing of CD8+ and CD8+-overlapped CD4+ epitope vaccine by targeting late and early proteins of human papillomavirus

  2018cites this paper
• Chitosan in Non-Viral Gene Delivery: Role of Structure, Characterization Methods, and Insights in Cancer and Rare Diseases Therapies

  2018cites this paper